Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.

International journal of body composition research Pub Date : 2013-01-28

Xingsheng Li, Tim R Nagy

{"title":"Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.","authors":"Xingsheng Li, Tim R Nagy","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice.Methods: Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography.Results: Olanzapine-treated mice tended to have lower trabecular bone volume (P = 0.088) and connectivity (P = 0.057) but no significant differences in bone density (P = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (P = 0.001) and volume (P = 0.008), bone volume/total volume (P = 0.001), connectivity (P = 0.007), and trabecular number (P = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment.Conclusion: AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.","PeriodicalId":87474,"journal":{"name":"International journal of body composition research","volume":"11 1","pages":"21-24"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023556/pdf/nihms460430.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of body composition research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice.

Methods: Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography.

Results: Olanzapine-treated mice tended to have lower trabecular bone volume (P = 0.088) and connectivity (P = 0.057) but no significant differences in bone density (P = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (P = 0.001) and volume (P = 0.008), bone volume/total volume (P = 0.001), connectivity (P = 0.007), and trabecular number (P = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment.

Conclusion: AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.

本刊更多论文

非典型抗精神病药物抑制C57BL/6J小鼠骨小梁增生。

目的:探讨非典型抗精神病药物奥氮平和利培酮对雌性C57BL/6J小鼠股骨骨特征的影响。方法:小鼠用安慰剂或AADs(奥氮平或利培酮)治疗3 ~ 4周。用显微计算机断层扫描确定股骨皮质和骨小梁的特征。结果:与对照组相比，奥氮平组小鼠骨小梁体积(P = 0.088)和连连性(P = 0.057)较低，骨密度差异无统计学意义(P = 0.521)。与对照组相比，利培酮治疗小鼠的骨小梁骨密度(P = 0.001)、体积(P = 0.008)、骨体积/总体积(P = 0.001)、连度(P = 0.007)和骨小梁数量(P = 0.003)均显著降低。奥氮平或利培酮治疗对皮质骨无明显影响。结论:AADs抑制C57BL/6J小鼠骨小梁增生，提示可能需要考虑有潜在骨质疏松风险的精神分裂症患者的替代治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of body composition research

自引率

0.00%

发文量